Diabetes drug to be limited over heart damage fears

Go Back   The Diabetes Forum Support Community For Diabetics Online > Diabetes Forum Start Here > Diabetes News

Diabetes News The Diabetes News section is a place to share any new stories or information you have come across related to Diabetes for the rest of the forum to share and discuss. If you have seen or read about new medication, diabetes treatments, medical breakthroughs or any interesting stories of personal interest then please post and discuss them here. From time to time we will take some of the Diabetes News stories from this section and write them up in our Diabetes Blog.


Diabetes drug to be limited over heart damage fears


Closed Thread
 
Shared Thread Thread Tools
Old 05-20-2008, 07:48   #1
 
Join Date: Feb 2008
Posts: 34


Default Diabetes drug to be limited over heart damage fears

THE prescribing of a drug widely used to treat diabetes is to be restricted after warnings which linked it to heart problems.
Drugs experts from NHS Greater Glasgow and Clyde ? Scotland's biggest health board ? have said only diabetes specialists should be allowed to begin treating a patient with Avandia.

for full story click on this link



george jacob is offline  
Old 06-14-2008, 04:39   #2
Senior Member
 
Anthill's Avatar
 
Join Date: May 2008
Location: Hastings Melbourne Australia
Posts: 663

Member Type
Type 1
Diagnosed in 1971

27 likes received
18 likes given
Send a message via MSN to Anthill Send a message via Yahoo to Anthill
Unhappy Cannot read article

The link just forced me to register and so cannot read the article. Can you just copy & paste in quote tags.

__________________

Type 1 Diabetic for 43 Years.
Insulins Novorapid and Levemir.
So I am well armed to enjoy food of any kind!!!
Peter...

Anthill is offline  
Old 06-15-2008, 15:49   #3
Senior Member
 
Richard157's Avatar
 
Join Date: Dec 2007
Location: Kingston, NY
Posts: 3,024

Member Type
Type 1
Diagnosed in 1945

931 likes received
936 likes given
Default

I have used Avandia for 9 years and my heart is string and healthy. Avandia should probably not be used by individuals who have a pre-existing heart problem or who have a history of heart problems among their relatives. My endo says that I should not have a problem with it since I am very healthy after using it for 9 years.

Richard157 is offline  
 
Old 06-15-2008, 21:46   #4
Senior Member
 
Ricky's Avatar
 
Join Date: May 2008
Location: Montreal ,Canada
Posts: 72


2 likes received
Default

Quote:
Originally Posted by Anthill View Post
The link just forced me to register and so cannot read the article. Can you just copy & paste in quote tags.
HEre Peter I found another place we're they talked about Avandia



FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA



FDA News
FOR IMMEDIATE RELEASE
P07-88
May 21, 2007
Media Inquiries:
Susan Cruzan, 301-827-6242
Consumer Inquiries:
888-INFO-FDA



FDA Issues Safety Alert on Avandia
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.

Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.

FDA's analyses of all available data are ongoing. FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies. Pending questions include whether the other approved treatment from the same class of drugs, pioglitazone, has less, the same or greater risks. Furthermore, there is inherent risk associated with switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments. For these reasons, FDA is not asking GlaxoSmithKline, the drug's sponsor, to take any specific action at this time. FDA is providing this emerging information to prescribers so that they, and their patients, can make individualized treatment decisions.

"FDA remains committed to assuring that doctors and patients have the latest information available to make treatment and medication use decisions. In this case, FDA is carefully weighing several complex sources of data, some of which show conflicting results, related to the risk of heart attack and heart-related deaths in patients treated with Avandia," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "We will complete our analyses and make the results available as soon as possible. FDA will take the issue of cardiovascular risk associated with Avandia and other drugs in this class to an Advisory Committee as soon as one can be convened."

Avandia was approved in 1999 for treatment of type 2 diabetes, a serious and life threatening disease that affects about 18 to 20 million Americans. Diabetes is a leading cause of coronary heart disease, blindness, kidney failure and limb amputation. Since the drug was approved, FDA has been monitoring several heart-related adverse events (e.g., fluid retention, edema and congestive heart failure) based on signals seen in previous controlled clinical trials of Avandia alone and in combination with other drugs, and from postmarketing reports. FDA has updated the product's labeling on several occasions to reflect these new data, most recently in 2006. The most recent labeling change for Avandia also included a new warning about a potential increase in heart attacks and heart-related chest pain in some individuals using Avandia. This new warning was based on the result of a controlled clinical trial in patients with existing congestive heart failure.

Recently, the manufacturer of Avandia provided FDA with a pooled analysis (meta analysis) of 42 randomized, controlled clinical trials in which Avandia was compared to either placebo or other anti-diabetic therapies in patients with type 2 diabetes. The pooled analysis suggested that patients receiving short-term (most studies were 6-months duration) treatment with Avandia may have a 30-40 percent greater risk of heart attack and other heart-related adverse events than patients treated with placebo or other anti-diabetic therapy. These data, if confirmed, would be of significant concern since patients with diabetes are already at an increased risk of heart disease.

Avandia is manufactured by GlaxoSmithKline, which is based in Research Triangle Park, N.C.

####

Additional Information

RSS Feed for FDA News Releases [what's this?]

Get free weekly updates about FDA press releases, recalls, speeches, testimony and more.

FDA Newsroom

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

FDA Website Management Staff



FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA



FDA News
FOR IMMEDIATE RELEASE
P07-88
May 21, 2007
Media Inquiries:
Susan Cruzan, 301-827-6242
Consumer Inquiries:
888-INFO-FDA



FDA Issues Safety Alert on Avandia
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia. However, other published and unpublished data from long-term clinical trials of Avandia, including an interim analysis of data from the RECORD trial (a large, ongoing, randomized open label trial) and unpublished reanalyses of data from DREAM (a previously conducted placebo-controlled, randomized trial) provide contradictory evidence about the risks in patients treated with Avandia.

Patients who are taking Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack should talk to their doctor about this new information as they evaluate the available treatment options for their type 2 diabetes.

FDA's analyses of all available data are ongoing. FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies. Pending questions include whether the other approved treatment from the same class of drugs, pioglitazone, has less, the same or greater risks. Furthermore, there is inherent risk associated with switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments. For these reasons, FDA is not asking GlaxoSmithKline, the drug's sponsor, to take any specific action at this time. FDA is providing this emerging information to prescribers so that they, and their patients, can make individualized treatment decisions.

"FDA remains committed to assuring that doctors and patients have the latest information available to make treatment and medication use decisions. In this case, FDA is carefully weighing several complex sources of data, some of which show conflicting results, related to the risk of heart attack and heart-related deaths in patients treated with Avandia," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "We will complete our analyses and make the results available as soon as possible. FDA will take the issue of cardiovascular risk associated with Avandia and other drugs in this class to an Advisory Committee as soon as one can be convened."

Avandia was approved in 1999 for treatment of type 2 diabetes, a serious and life threatening disease that affects about 18 to 20 million Americans. Diabetes is a leading cause of coronary heart disease, blindness, kidney failure and limb amputation. Since the drug was approved, FDA has been monitoring several heart-related adverse events (e.g., fluid retention, edema and congestive heart failure) based on signals seen in previous controlled clinical trials of Avandia alone and in combination with other drugs, and from postmarketing reports. FDA has updated the product's labeling on several occasions to reflect these new data, most recently in 2006. The most recent labeling change for Avandia also included a new warning about a potential increase in heart attacks and heart-related chest pain in some individuals using Avandia. This new warning was based on the result of a controlled clinical trial in patients with existing congestive heart failure.

Recently, the manufacturer of Avandia provided FDA with a pooled analysis (meta analysis) of 42 randomized, controlled clinical trials in which Avandia was compared to either placebo or other anti-diabetic therapies in patients with type 2 diabetes. The pooled analysis suggested that patients receiving short-term (most studies were 6-months duration) treatment with Avandia may have a 30-40 percent greater risk of heart attack and other heart-related adverse events than patients treated with placebo or other anti-diabetic therapy. These data, if confirmed, would be of significant concern since patients with diabetes are already at an increased risk of heart disease.

Avandia is manufactured by GlaxoSmithKline, which is based in Research Triangle Park, N.C.

####

Additional Information

RSS Feed for FDA News Releases [what's this?]

Get free weekly updates about FDA press releases, recalls, speeches, testimony and more.

FDA Newsroom

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

FDA Website Management Staff

__________________
Hi i'm Richard alias Ricky fromMontreal Canada
Type II since 1993 meds +humalog humalin n .Parkinson disease since 2005
Bye Ricky
Ricky is offline  
Old 06-17-2008, 10:36   #5
Senior Member
 
Anthill's Avatar
 
Join Date: May 2008
Location: Hastings Melbourne Australia
Posts: 663

Member Type
Type 1
Diagnosed in 1971

27 likes received
18 likes given
Send a message via MSN to Anthill Send a message via Yahoo to Anthill
Default

Thankyou Richard, You are a marvel mate.

__________________

Type 1 Diabetic for 43 Years.
Insulins Novorapid and Levemir.
So I am well armed to enjoy food of any kind!!!
Peter...

Anthill is offline  
Old 02-09-2009, 15:18   #6
Active Member
 
Join Date: Oct 2008
Location: Living in J&K State of India
Posts: 14

Member Type
Type 2
Diagnosed in 1992

2 likes received
1 likes given
Default

Quote:
Originally Posted by Anthill View Post
Thankyou Richard, You are a marvel mate.
Helo friends,

asprine is known to prevent clotting,but at the same time it may
lead to haemmorhages leading to damages to retina or kidneys,thus enhancing diabetic complications.The use of asprine has to be under medical care.

krishanlalgupta is offline  
Closed Thread

Thread Tools

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
3) Resveratrol In Grape Skins Could Stop Diabetic Complications Such As Heart Disease george jacob Diabetes Treatment 1 03-30-2009 10:33
Mechanisms Suggest New Way To Treat Heart Disease Among Diabetics george jacob Diabetes News 0 03-18-2008 12:53
Drug Interactions Checker Richard157 Diabetes Medication and Supplies 0 12-21-2007 21:39

LEGAL NOTICE
By using this Website, you agree to abide by our Terms and Conditions (the "Terms"). This notice does not replace our Terms, which you must read in full as they contain important information. You must not post any defamatory, unlawful or undesirable content, or any content copied from a third party, on the Website. You must not copy material from the Website except in accordance with the Terms. This Website gives users an opportunity to share information only and is not intended to contain any advice which you should rely upon. It does not replace the need to take professional or other advice. We have no liability to you or any other person in respect of any content on this Website.


All times are GMT +1. The time now is 20:08.




Powered by vBulletin®
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Search Engine Optimization by vBSEO
vBulletin Security provided by vBSecurity v2.2.2 (Pro) - vBulletin Mods & Addons Copyright © 2020 DragonByte Technologies Ltd.
User Alert System provided by Advanced User Tagging v3.1.0 (Pro) - vBulletin Mods & Addons Copyright © 2020 DragonByte Technologies Ltd.